ROPA-DOP Study_ NA_00083629, 8/8/13 
 
 
1 
  
 
Study Protocol 
 
 
Randomized Evaluation of Heart Failure with Preserved Ejection Fraction 
(HFpEF) Patients with Acute Hear t Failure and Dopamine (ROPA-OP ) Trial 
 
clinicaltrials.gov Identifier: [STUDY_ID_REMOVED] 
  
Protocol Date: August 8, 2013 
  
Principal Investigator: 
[INVESTIGATOR_104727], MD 
The Johns Hopkins University School of Medicine. 
[ADDRESS_116127], Carnegie 568 
Baltimore, MD [ZIP_CODE] 
Phone: [PHONE_2402]  Fax: [PHONE_2403] 
 
 
  
ROPA-DOP Study_ NA_00083629, 8/8/13 
 
 
2 
 JHM IRB - eForm A – Study Protocol  
 
  
 Use the section headings to write the JHM IRB eForm A, insertin g the appropriate 
material in each. If a section i s not applicable, leave heading in and insert N/A. 
 When submitting JHM IRB eForm A (new or revised), enter the dat e submitted to 
the field at the top of JHM IRB eForm A. 
 
*************************************************************************************************** 
 
 
1. Abstract 
a. Provide no more than a one page research abstract briefly stati ng the problem, 
the research hypothesis, and the importance of the research. 
 
 
Heart Failure with preserved Eje ction Fraction (HFPEF) accounts  for 40-50% of all 
heart failure patients with a frequency of hospi[INVESTIGATOR_104728] t erm mortality similar to pat ients with heart 
failure with reduced ejection fra ction (HFREF). Patients with H FPEF are often 
preload dependent and despi[INVESTIGATOR_104729] (ADHF), are typi[INVESTIGATOR_104730]. In contrast  to the many randomized trials showing mortality and 
morbidity benefit of ACE inhibito rs and beta blockers in patien ts with heart failure 
with reduced ejection fracti on, no drugs have shown a benefit in patients with 
HFPEF. Furthermore, patients hospi[INVESTIGATOR_104731], more frequent re-
hospi[INVESTIGATOR_104732], and worse short term surviv al compared to those 
without acute kidney injury. We  hypothesize that changing the m ethod of diuresis 
and/or the addition of low-dose  dopamine for the treatment of ADHF in patients with 
HFPEF will reduce renal injury, resulting in a shorter length o f stay, and decrease 
hospi[INVESTIGATOR_104733]. 
 
 
2. Objectives (include all prim ary and secondary objectives) 
 
To evaluate the effects of low dose dopamine and diuretic strat egy (intermittent versus 
continuous) on renal function in patients with HFPEF admitted w ith acute heart failure.  
 Primary end point:  
1. Percent change in creatinine from randomization to 72 hrs from treatment 
protocol initiation. 
Secondary end points: 
1. Change in incidence of acute kidn ey injury (AKI) as defined by [CONTACT_104742]: Improving Global Outcom es (KDIGO criteria summarized b elow) 
from randomization to 72 hrs.
1  
R O P A - D O P  S t u d y _  N A _ 0 0 0 8 3 6 2 9 ,  8 / 8 / 1 3  
 
 
3  
 2 .  I n c i d e n c e  o f  A K I  a s  d e t e rm i n e d  b y  u r i n e  o u t p u t  a t  7 2  h r s  ( K D I G O  c r i t e r i a ,  
s umm a r i z e d  b e l o w ) . 1 
3 .  C h a n g e  i n  c r e a t i n i n e  a t  7 2  h r s  a d j u s t e d  f o r  v o l um e  o f  f l u i d  r em o v a l  
4 .  C h a n g e  i n  s e r um  c y s t a t i n  C  r a n d om i z a t i o n  t o  7 2  h r s  
5 .  C h a n g e  i n  N T  p r o - B N P  f r om  r a n d om i z a t i o n  t o  7 2  h r s   
6 .  V o l um e  o f  d i u r e s i s  m e a s u r e d  i n  l i t e r s  
a )  C um u l a t i v e  v o l um e  o f  d i u r e s i s  m e a s u r e d  i n  l i t e r s  
b )  C um u l a t i v e  v o l um e  o f  d i u r e s i s  m e a s u r e d  i n  l i t e r s  a d j u s t e d  f o r  B S A  
7 .  N e t  w e i g h t  l o s s  a t  7 2  h r s  i n  k g   
8 .  N e e d  f o r  i n c r e a s e  i n  i n t r a v e n o u s  d i u r e t i c  d o s e  
9 .  C h a n g e  i n  d i s t a n c e  d u r i n g  6  m i n u t e  w a l k  t e s t   
a )  F r om  a dm i s s i o n  t o  7 2  h r s  
b )  F r om  a dm i s s i o n  t o  d i s c h a r g e  
1 0 .  G l o b a l  w e l l - b e i n g  a s s e s sm e n t  s c o r e  f r om  a dm i s s i o n  t o  7 2  h r s ,  a n d  a t  
d i s c h a r g e .   T o  b e  a s s e s s e d  b y  a  V i s u a l  A n a l o g  S c a l e  ( V A S ) .   
1 1 .  S u b j e c t i v e  d y s p n e a  s c o r e  f r om  a dm i s s i o n  t o  7 2  h r s ,  a n d  a t  d i s c h a r g e .  T o  b e  
a s s e s s e d  b y  a  V i s u a l  A n a l o g  S c a l e  ( V A S ) .   
1 2 .  C h a n g e  i n  f r a i l t y  i n d e x  f r om  a dm i s s i o n  t o  7 2  h r s ,  a n d  a t  d i s c h a r g e .  T o  b e  
a s s e s s e d  b y  t h e  J o h n s  H o p k i n s  O l d e r  Am e r i c a n s  I n d e p e n d e n c e  C e n t e r  O n l i n e  
F r a i l t y  A s s e s sm e n t  T o o l   
1 3 .  L e n g t h  o f  s t a y  o f  h o s p i t a l i z a t i o n  i n  d a y s  
1 4 .  3 0  d a y ,  6  m o n t h ,  a n d  1  y e a r  h o s p i t a l  r e a dm i s s i o n  o r  E R  v i s i t  f o r  m a j o r  
a d v e r s e  c a r d i o v a s c u l a r  e v e n t ,  h e a r t  f a i l u r e ,  r e n a l  f a i l u r e  ( d e v e l o pm e n t  o f  
C K D ,  E S R D ,  o r  d i a l y s i s  n e e d  b y  K D I G O  c r i t e r i a ) ,  s y n c o p e ,  o r  a r r h y t hm i a .  
R e a dm i s s i o n  e v e n t s  w i l l  b e  a d j u d i c a t e d  b y  a  C l i n i c a l  E v e n t  C omm i t t e e  
c o n s i s t i n g  o f  2 - 3  c a r d i o l o g i s t s  n o t  d i r e c t l y  i n  c o n t a c t  w i t h  p a t i e n t s  e n r o l l e d  i n  
t h e  s t u d y .  
 
K D I G O  A K I  D e f i n i t i o n 1:   
 
A K I  i s  d e f i n e d  b y  a n y  o f  t h e  f o l l o w i n g  3  c r i t e r i a :   
1 .  I n c r e a s e  i n  s e r um  c r e a t i n i n e  b y  ≥ 0 . 3  m g / d l  ( ≥  2 6 . 5  μm o l / l )  w i t h i n  4 8  
h o u r s ;  O R   
2 .  I n c r e a s e  i n  s e r um  c r e a t i n i n e  t o  ≥ 1 . 5  t im e s  b a s e l i n e ,  w h i c h  i s  k n o w n  o r  
p r e s um e d  t o  h a v e  o c c u r r e d  w i t h i n  p r i o r  7  d a y s ;  O R   
3 .  U r i n e  v o l um e  < 0 . 5  m l / k g / h  f o r  6  h o u r s   
S t a g e s  o f  A K I  a s  d e f i n e d  b y  K D I G O  C r i t e r i a  a r e  a s  f o l l o w s :   
≥ ≥
R O P A - D O P  S t u d y _  N A _ 0 0 0 8 3 6 2 9 ,  8 / 8 / 1 3  
 
 
4  
 ≥
≥ ≥≥
≥
 
3 .  B a c k g r o u n d  ( b r i e f l y  d e s c r i b e  p r e - c l i n i c a l  a n d  c l i n i c a l  d a t a ,  c u r r e n t  e x p e r i e n c e  w i t h  
p r o c e d u r e s ,  d r u g  o r  d e v i c e ,  a n d  a n y  o t h e r  r e l e v a n t  i n f o rm a t i o n  t o  j u s t i f y  t h e  
r e s e a r c h )  
 
I t  i s  e s t im a t e d  t h a t  t h e r e  a r e  6 . 6  m i l l i o n  p a t i e n t s  w i t h  h e a r t  f a i l u r e  i n  t h e  U n i t e d  S t a t e s ,  a  
p r e v a l e n c e  o f  n e a r l y  3%  o f  U S  a d u l t s  o v e r  t h e  a g e  o f  1 8  y e a r s . 2  I n  2 0 0 8 ,  a n  e s t im a t e d  
2 8 0 , 0 0 0  d e a t h s  w e r e  a t t r i b u t e d  t o  h e a r t  f a i l u r e  a n y -m e n t i o n . 2 I n  2 0 0 9 ,  t h e r e  w e r e  a n  
e s t im a t e d  o v e r  1  m i l l i o n  h o s p i t a l  d i s c h a r g e s  f o r  h e a r t  f a i l u r e ,  m a k i n g  a c u t e  
d e c om p e n s a t e d  h e a r t  f a i l u r e  ( A D H F )  t h e  m o s t  c omm o n  c a u s e  o f  h o s p i t a l  a dm i s s i o n  i n  
p a t i e n t s  o v e r  t h e  a g e  o f  6 5 . 2 O f  t h i s  p o p u l a t i o n ,  u p  t o  3 8  t o  6 0%  h a v e  p r e s e r v e d  l e f t  
v e n t r i c u l a r  s y s t o l i c  f u n c t i o n ,  o r  h e a r t  f a i l u r e  w i t h  p r e s e r v e d  e j e c t i o n  f r a c t i o n  ( H F P E F ) . 3 - 4  
T h e  r e p o r t e d  m o r b i d i t y  a n d  m o r t a l i t y  o f  t h i s  p a t i e n t  p o p u l a t i o n  i s  e q u a l  t o  o r  s l i g h t l y  
b e t t e r  t h a n  t h a t  o b s e r v e d  i n  h e a r t  f a i l u r e  w i t h  r e d u c e d  e j e c t i o n  f r a c t i o n  ( H F R E F ) . 3 ,  5  
L a r g e ,  r a n d om i z e d  c o n t r o l l e d  t r i a l s  s t u d y i n g  p h a rm a c o l o g i c  t r e a tm e n t s  h a v e  f a i l e d  t o  
s h o w  c o n s i s t e n t  b e n e f i t  i n  t h e  H F P E F  p o p u l a t i o n .  W i t h  a  b u r g e o n i n g  p o p u l a t i o n  w i t h  t h e  
H F P E F  d i a g n o s i s ,  t h e r e  i s  m u c h  n e e d  t o  b e t t e r  u n d e r s t a n d  t h e  a s s o c i a t e d  r i s k  f a c t o r s ,  
p r e d i c t o r s  o f  m o r b i d i t y  a n d  m o r t a l i t y ,  a n d  p o t e n t i a l  t r e a tm e n t s  t h a t  m a y  o f f e r  im p r o v e d  
q u a l i t y  o f  l i f e  a n d  m o r t a l i t y  b e n e f i t  i n  t h i s  p o p u l a t i o n .   
 
P a t i e n t s  w i t h  H F P E F  a n d  H F R E F  a r e  t r e a t e d  w i t h  i n t r a v e n o u s  d i u r e t i c s  w h e n  a dm i t t e d  t o  
t h e  h o s p i t a l  w i t h  a c u t e  d e c om p e n s a t e d  h e a r t  f a i l u r e  a s  p a r t  o f  s t a n d a r d  t h e r a p y .  I n  
c o n t r a s t  t o  p a t i e n t s  w i t h  H F R E F ,  t h e  b e s t  m e c h a n i sm s  t o  a c h i e v e  s a f e  a n d  a d e q u a t e  
d i u r e s i s  i n  p a t i e n t s  w i t h  H F P E F  a r e  u n k n o w n . 6 - 7  O u r  r e t r o s p e c t i v e  e x p e r i e n c e  
( N A _ 0 0 8 2 0 3 5 )  s h o w s  t h a t  w i t h  i n t e r m i t t e n t  i n t r a v e n o u s  d i u r e t i c  t h e r a p y ,  a p p r o x im a t e l y  
5 0%  o f  p a t i e n t s  w i t h  H F P E F  e x p e r i e n c e  a c u t e  k i d n e y  i n j u r y  d e f i n e d  a s  a  c r e a t i n i n e  r i s e  >  
0 . 3  m g / d L  a n d  / o r  r e l a t i v e  i n c r e a s e  i n  c r e a t i n i n e  o f  >  2 5%  o v e r  t h e  c o u r s e  o f  t h e i r  
i n p a t i e n t  h o s p i t a l i z a t i o n .  A c u t e  k i d n e y  i n j u r y  i n  a  h o s p i t a l i z e d  h e a r t  f a i l u r e  p o p u l a t i o n  i s  
a s s o c i a t e d  w i t h  p r o l o n g e d  l e n g t h  o f  s t a y ,  m o r e  f r e q u e n t  r e a dm i s s i o n s ,  a n d  i n c r e a s e d  s h o r t  
t e rm  m o r t a l i t y . 8 S t u d i e s  h a v e  d em o n s t r a t e d  i n  H F R E F  p a t i e n t s  t h a t  a  m i l d  r e d u c t i o n  i n  
g l om e r u l a r  f i l t r a t i o n  r a t e  ( i n c r e a s e  i n  p l a sm a  c r e a t i n i n e  o f  0 . 2 - 0 . 3  m g / d L )  h a s  a n  im p a c t  
o n  p a t i e n t  s u r v i v a l ,  e v e n  i n  t h o s e  w h o  w e r e  a s ym p t om a t i c . 9 - 1 0  E f f o r t s  t o  a c h i e v e  a n  
ROPA-DOP Study_ NA_00083629, 8/8/[ADDRESS_116128] suggested a possible 
benefit with continuous infusi on diuretic therapy compared to i ntermittent bolus dosing. 
However, the Diuretic Optimizati on Strategies Evaluation (DOSE)  trial demonstrated that 
patients with HFREF admitted w ith ADHF had no significant diffe rence in patients’ 
global assessment of symptoms or in the change in renal functio n when diuretic therapy 
was administered as intermittent bolus dosing versus continuous  infusion, or at high 
compared to low dosing protocols.
[ADDRESS_116129] also not consistently shown clinical or 
renal protective benefit, incl uding nesiritide, nitroprusside, nitroglycerine, and 
dobutamine.
11-14 Dopamine is a catecholamine that  exhibits dose-dependent effects on the 
systemic and renal vasculature .  At low doses (≤ 3 µg/kg/min), it has been found to act on 
the A1 receptors, resulting in vas odilatation of the renal arteries in addition to the 
mesenteric, coronary, and cereb ral vascular beds. The use of lo w-dose or “renal-dose” 
dopamine in ADHF has been proposed as a renal protective therap y. A large meta-
analysis of [ADDRESS_116130] suggested that 
low-dose dopamine may increase renal blood flow and GFR in stab le patients with 
HFREF.16-17 The Dopamine in Acute Decompen sated Heart Failure (DAD-HF) tri al 
randomized 60 patients to either high-dose furosemide, or low-d ose furosemide in 
combination with low-dose dopamine with a primary endpoint of w orsening renal 
function. The trial demonstrate d significantly higher incidence  of renal impairment in the 
high-dose furosemide treatment group compared with the low-dose  furosemide with 
dopamine group.7 It is important to note that t he data available to date on the  effects of 
low-dose dopamine in heart failure is predominantly from patien ts with reduced ejection 
fraction (HFREF) patients; exceedingly limited data is availabl e on the use of this therapy 
in the HFPEF population.   Given the increasing incidence and prevalence of HFPEF, with associated morbidity and 
mortality nearing that of systoli c heart failure, it is imperat ive to better understand and 
assess treatment strategies i n this patient population. To date , our management of ADHF 
in HFPEF patients has been large ly extrapolated from treatment strategies used in 
ROPA-DOP Study_ NA_00083629, 8/8/[ADDRESS_116131] to many of these treatments , including diuretic strategy an d the use of renal 
protective agents, such as low -dose dopamine. Thus, further inv estigation of the efficacy 
and safety of these treatments in the HFPEF population is warra nted.  
 
   
4. Study Procedures  
a. Study design, including the se quence and timing of study proced ures   
(distinguish research procedures from those that are part of ro utine care). 
 
This is a prospective, randomized, non-blinded study. The outcome variable collection 
will be blinded. Subjects will be randomized (1:1:1:1) within 2 4 hours of admission for 
acute decompensated heart failu re to one of four treatment grou ps: 
 Treatment Protocol :  
 1. Intermittent bolus (every 12 hrs) furosemide diuretic therapy 
2. Continuous infusion furosem ide diuretic therapy 
3. Intermittent bolus (every 12 hrs) furosemide diuretic therapy p lus infusion of low 
dose intravenous dopamine (3 µg/kg/min) 
4. Continuous infusion furosemide di uretic therapy plus infusion of low dose 
intravenous dopamine (3 µg/kg/min) 
 
Each treatment arm protocol  is detailed as follows:  
1. Intermittent bolus furosemide diuretic therapy:   
a. If the patient is not on a prior d iuretic dose, a standard dose  of furosemide 
40mg IV every 12 hrs, with total  dose of 80 mg IV over 24 hrs w ill be 
initiated.  
b. If the patient is already on a prescribed diuretic dose, their outpatient dose will 
be doubled and administered as the equivalent IV dose every 12 hrs. Note: 
standard furosemide dosing has a 2:1 oral to IV ratio when dosi ng. 
i. Example: If the prescribed hom e dose is furosemide 80mg by [CONTACT_104743] h twice 
daily, the inpatient treatment dose will be the IV equivalent o f furosemide 160 
by [CONTACT_104744] (double the  home dose).  Therefore, the in patient 
treatment dose would be furosem ide 80mg IV twice daily).  
2. Continuous infusion furosem ide diuretic therapy 
a. If the patient is not on a prior d iuretic dose, a standard dose  of furosemide 
80mg IV over 24 hrs, w ill be initiated.  
b. If the patient is already on a prescribed diuretic dose, their outpatient dose will 
be doubled and administered as the equivalent IV dose, continuo usly over 24 
hrs. Note: standard furosemide  dosing has a 2:1 oral to IV rati o when dosing. 
i. Example: If the prescribed hom e dose is furosemide 80mg by [CONTACT_104743] h twice 
daily (160mg total per day), the i npatient treatment dose will be the IV 
equivalent of furosemide 320m g total per day.  Therefore, the i npatient 
treatment dose would be furosemid e 160mg IV administered contin uously 
over 24 hrs. 
ROPA-DOP Study_ NA_00083629, 8/8/13 
 
 
7 
  
 
3. Intermittent bolus (every 12 hrs) furosemide diuretic therapy p lus infusion of low 
dose intravenous dopamine (3 µg/kg/min) 
a. Intermittent furosemide diuretic therapy from above (1.) with t he addition of 
dopamine at 3 µg/kg/min  
4. Continuous infusion furosemide di uretic therapy plus infusion of low dose 
intravenous dopamine (3 µg/kg/min) 
a. Continuous furosemide diuretic  therapy from above (2.) with the addition of 
dopamine at 3 µg/kg/min 
 Conversion guidelines:    2 mg oral furosemide = 1 mg intravenous furosemide  
1 mg torsemide = 2 mg furosemide  1 mg bumetanide = 40 mg furosemide 
 
 Diuretic titration guidelines: 
 
Should the patient fail to demons trate adequate diuresis (net n egative urine output of at 
least 500ml in 12 hrs) in response to the first treatment dose,  the subsequent diuretic dose 
to be administered 12 hrs later (dose #2) will be doubled, or t he continuous infusion will 
be doubled, with the goal of net  negative urine output of 1 liter over 24 hrs.  This titration 
plan can continue until adequate diuresis is achieved (at least  net negative 1L urine output 
over 24 hr period). 
Maximum Diuretic Dose:  
 
The maximum dose permitted within study protocol will be furosemide 200 IV twice daily, or a total dose of furosemide 400 IV over 24 hrs.  Shoul d the primary team feel the 
patient needs higher dosing or the addition of a thiazide diure tic (or alternative agent), the 
patient will be considered treatment failure and will be remove d from the study.  
 Electrolyte Repletion Guidelines :  
The primary team will obtain basi c metabolic panels on all stud y participants every 12 
hours for the duration of the study.  It will be the responsibi lity of the primary team to 
replete electrolytes with t he goals of potassium > 4.0, and magnesium >2.0 as needed for 
study participants.   Fluid and Salt Restrictions:  
Each study participant will be maintained on a daily 2 liter fl uid and 2 gm sodium 
restricted diet, to be ordered by [CONTACT_96204].    
Treatment beyond trial end-point guidelines:  
 
ROPA-DOP Study_ NA_00083629, 8/8/[ADDRESS_116132].  
 
All other heart failure or non-h eart failure treatments will be  left to the discretion of the 
primary team from the time of the  patient’s admission to the ho spi[INVESTIGATOR_3491]/or enrollment in 
the study.  This includes anti-hype rtensives, anti-arrhythmic d rugs, and any other 
therapi[INVESTIGATOR_104734] t he treatment of the study subje ct.   
 After 72 hrs, the study drug will be discontinued, a primary assessment will be made of primary and secondary endpoints, and all further treatment is a t the treating physician’s 
discretion.  
 
Note:  Study participants will be permitted to cross over into non-assigned arms of the 
study, however the study analysis will be completed as an inten tion-to-treat study.  It will 
be left to the discretion of th e primary team, with supervision  from the study investigators 
as to whether a cross over is necessary within the 72 hr study time frame.   Baseline Assessments and Data to be Recorded (all are standard of care unless 
indicated by *) 
1. Directed history and physical ex am, focused on signs and sympto ms of 
congestion/volume overload 
2. Vital signs (HR, BP, O2 sa turation, weight, height) 
3. Home medications 
4. Basic metabolic panel including ser um creatinine, BUN, electrolytes and 
magnesium 
5. Serum Pro-BNP level 
6. Serum Cystatin C* 
7. High-sensitivity troponin  
8. Baseline electrocardiogram 
9. Transthoracic echocardiogram if one has not been obtained withi n 1 year prior to 
admission  
i. Including left ventricular (LV)  ejection fraction, LV dimension s, left 
atrium size (LA), LV mass, right ventricular function parameter s (RVSP), 
valvular assessment  
10. [ADDRESS_116133]*  
11. Patient Global Well being assessment by [CONTACT_8298]*  
12. Dyspnea  assessment by [CONTACT_8298]* 
13. Frailty Index* 
14. Blood sample for biomarkers and genetic testing for heart failu re* 
15. Urine sample for biomarkers* 
 24 hr Assessment :  
1. Routine vitals assessment with weight recording  
2. I/O assessment – to be recorded and totaled for each 12 period 
3. Twice daily basic metabolic panel and serum magnesium 
ROPA-DOP Study_ NA_00083629, 8/8/13 
 
 
9 
  
72 hr Assessment and Data to be Recorded :  
1. Routine vitals assessment with weight recording  
2. I/O assessment – to be recorded and totaled for each 24 period 
3. Twice daily basic metabolic panel and serum magnesium 
4. Serum Pro-BNP level* 
5. Serum Cystatin C* 
6. High-sensitivity troponin  
7. [ADDRESS_116134]*  
8. Patient Global Well being assessment by [CONTACT_8298]*  
9. Dyspnea  assessment by [CONTACT_8298]* 
10. Frailty Index* 
11. Changes in cardiovascular medications 
12. Assessment for serious cardiovascular events 
 
At Discharge Assessment and Data to be recorded:  
1. Routine vitals assessment wit h discharge weight recording  
2. I/O assessment – to be recorded and totaled for each 24 period 
3.  Basic metabolic panel including creatinine, BUN 
4. Serum Pro-BNP level 
5. Serum Cystatin C*  
6. High-sensitivity troponin  
7. [ADDRESS_116135]*  
8. Patient Global Well being assessment by [CONTACT_8298]* 
9. Dyspnea assessment by [CONTACT_8298]* 
10. Frailty Index* 
11. Changes in cardiovascular medications 
12. Assessment for serious cardiovascular events 
13. Urine and serum samples for biomarkers* 
 
*Investigational data to be to c ollected as part of trial proto col.  
 
Day 30, 6 month, and 1 year Assessment and Data to be Recorded:   
Patient charts will be reviewed and patients will receive a pho ne call to assess for 
potential re-hospi[INVESTIGATOR_4355] m ajor adverse cardiovascular events at each respective 
endpoint since discharge. The fir st readmission event following index hospi[INVESTIGATOR_104735] a Clinical Event Committee consisting of 2-[ADDRESS_116136] with patients enrolled in the study. 
 
 
 Vascular Access:  
 All patients in the intermitten t bolus diuretic strategy arm w ill require the 
placement of two functioning peripheral IV catheter.  Patients assigned to the continuous 
diuretic strategy and either treat ment arm that requires low-do se dopamine will need at 
least 2 peripheral IVs suitable for continuous infusions.  Cent ral venous catheter 
placement may be required shoul d it be difficult to obtain or m aintain peripheral IV 
ROPA-DOP Study_ NA_00083629, 8/8/13 
 
 
10 
 access.  This would be determined by [CONTACT_96204], with con sent obtained separately 
for this procedure by [CONTACT_96204].  
 
 Foley Catheter Placement:  
All patients enrolled in this t rial will be encouraged to have a foley urinary 
catheter placed.  This will allow for improved patient toleranc e of diuresis and improved 
accuracy of I/O assessment by [CONTACT_75462].  This will not be required, however, for 
enrollment in the trial.  
 
b. Study duration and number of st udy visits required of research participants. 
The study duration is the hospi [INVESTIGATOR_063].  The study drugs will be mandated for [ADDRESS_116137] to diuretics to aid in diuresis. 
 
e. Justification for inclusion of  a placebo or non-treatment group. 
There is no placebo group.  
f. Definition of treatment failure or participant removal criteria . 
Subjects will be removed from the protocol for: 1. The development of hemodynamic instability including hypotensio n (SBP < 90), 
hypertensive emergency, or unstabl e arrhythmias (SVT or VT). 
2. The development of pulmonary ede ma requiring inotropes or vasop ressor or more 
than 50% inspi[INVESTIGATOR_1401]. 
3. The development of acute coronary syndrome. 
4. The development of acute kidne y injury by [CONTACT_104745]
1:  
a. If the patient develops Stage II AKI (by [CONTACT_104746]), the s tudy 
treatment will be held and a clin ical decision will be made whe ther to 
resume or discontinue treatment drug 
b. If the patient develops Stage I II AKI (by [CONTACT_104746]), the study 
treatment will be discontinue d and the patient will be classifi ed as 
treatment failure and followed only for outcome recording.  
5. The need for renal replacement therapy 
6. New atrial fibrillation or other supraventricular tachyarrhythm ia 
7. Sustained ventricular arrhythmias 
ROPA-DOP Study_ NA_00083629, 8/8/13 
 
 
11 
 8. Requirement of furosemide dose increase beyond the study maximu m of 200 IV 
twice daily (or 400 IV over 24 hrs), or the need for addition o f thiazide diuretic.  
 
g. Description of what happens to p articipants receiving therapy w hen study ends or if a 
participant’s participation in  the study ends prematurely. 
Once the study period ends, or if the study ends prematurely, t he patient will receive 
standard heart failure managem ent at the discretion of the prim ary team. The patient 
will resume standard outpatient follow up as advised by [CONTACT_104747].  
 
5. Inclusion/Exclusion Criteria 
 
a. Inclusion Criteria : 
1. Admission to the hospi[INVESTIGATOR_104736] [ADDRESS_116138] 1 
symptom (dyspnea, orthopnea, or  edema) AND 1 sign (rales on 
auscultation, elevated jugular  venous pulse, hepatojugular refl ex, 
peripheral edema, ascites, pulmonary vascular congestion on 
chest radiography)  
2. Patient ≥18 years of age   
3. Estimated GFR of > 15mL/min/1.73m2 determined by [CONTACT_104748][INVESTIGATOR_10444] (CKD- EPI) equation  
4. Willingness to provide informed consent  
5. Known ejection fraction by [CONTACT_104749] > 50% within [ADDRESS_116139] in a f emale of child bearing potential 
7. Willingness of primary attending physician for patient to parti cipate. 
 
b. Exclusion: 
1. Systolic BP <90 mmHg on admission 
2. Hemoglobin (Hgb) < 8 g/dl 
3. Known allergy or intolerance to f urosemide or low dose dopamine . 
4. Hemodynamically significant arrhythmias including supraventricu lar 
tachycardias not responsive to rat e control therapi[INVESTIGATOR_104737], ventricular tachycardia, or defibrilla tor shock 
within 4 weeks 
5. Acute coronary syndrome within 4 weeks as defined by [CONTACT_104750] 
(ECG) ST-segment depression or prominent T-wave inversion and/o r 
positive biomarkers of necrosis (e.g., troponin) in the absence  of ST-segment 
elevation and in an appropriate c linical setting (chest discomf ort or anginal 
equivalent) 
6. Cardiac diagnoses in addition to or other than HFPEF:  
i. Active myocarditis 
ii. Hypertrophic obstructive cardiomyopathy 
iii. Severe valvular disease 
ROPA-DOP Study_ NA_00083629, 8/8/13 
 
 
12 
 iv. Restrictive or constrictive cardiomyopathy, including known 
amyloidosis, sarcoidosis, hemochromatosis 
v. Complex congenital heart disease 
vi. Constrictive pericarditis 
vii. Severe pulmonary hypertension ( RVSP ≥ 60), not secondary to 
HFPEF 
7. Non-cardiac pulmonary edema 
8. Clinical evidence  of digoxin toxicity 
9. Received IV vasoactive treatment or ultra-filtration therapy fo r heart failure 
since initial presentation 
10. Anticipated need for IV vasoact ive treatment or ultra-filtratio n for heart 
failure during this hospi[INVESTIGATOR_059] 
11. History of temporary or permanent  renal replacement therapy or 
ultrafiltratio n within 6 months 
12. History of renal artery stenosis > 50% 
13. Need for mechanical hemodynamic support 
14. Sepsis 
15. Terminal illness (other than HF) with expected survival of less  than 1 year 
16. Previous adverse reac tion to the study drugs 
17. Enrollment or planned enrollment in another randomized clinical  trial during 
this hospi[INVESTIGATOR_059] 
18. Inability to comply with planned study procedures 
19. Pregnancy or nursing mothers 
 
 
 
6. Drugs/ Substances/ Devices a. The rationale for choosing the drug and dose or for choosing th e device to be 
used. 
 
Furosemide is that standard of car e diuretic for patients admit ted to the hospi[INVESTIGATOR_104738] . Dopamine at low dose is ofte n used to assist 
diuresis and reduce acute kidney injury in patients at high ris k for acute kidney injury 
with heart failure from systolic dysfunction.  
b. Justification and safety information if FDA approved drugs will  be administered 
for non-FDA approved indications  or if doses or routes of administration or 
participant populations are changed.  N/A.   
 
c. Justification and safety informa tion if non-FDA approved drugs without an IND 
w
ill be administered.  
 
N/A  
ROPA-DOP Study_ NA_00083629, 8/8/13 
 
 
13 
  
  
 7. Study Statistics 
a. Primary outcome variables. 
1. Percent change in creatinine from randomization to 72 hrs from 
treatment protocol initiation. 
  
b. Secondary outcome variables. 
1. Change in incidence of acute kidn ey injury (AKI) as defined by [CONTACT_104742]: Improving Global Outcom es (KDIGO criteria summarized b elow) 
from randomization to 72 hrs.
1  
2. Incidence of AKI as determin ed by [CONTACT_104751] 72 hrs (KDIGO  criteria, 
summarized below).1 
3. Change in creatinine at 72 hrs ad justed for volume of fluid removal 
4. Change in serum cystatin C  randomization to 72 hrs 
5. Change in NT pro-BNP from randomization to 72 hrs  
6. Volume of diuresis measured in liters 
c) Cumulative volume of diuresis measured in liters 
d) Cumulative volume of diuresis meas ured in liters adjusted for B SA 
7. Net weight loss at [ADDRESS_116140]  
c) From admission to 72 hrs 
d) From admission to discharge 
10. Global well-being assessment score from admission to 72 hrs, an d at 
discharge.  To be assessed by a Visual Analog Scale (VAS).  
11. Subjective dyspnea score from admission to 72 hrs, and at disch arge. To be 
assessed by a Visual Analog Scale (VAS).  
12. Change in frailty index from admission to 72 hrs, and at discha rge. To be 
assessed by [CONTACT_104752]  
13. Length of stay of hospi[INVESTIGATOR_104739] 
14. 30 day, 6 month, and 1 year hospi[INVESTIGATOR_104740] r major 
adverse cardiovascular event, hear t failure, renal failure (dev elopment of 
CKD, ESRD, or dialysis need by [CONTACT_104746]), syncope, or arr hythmia. 
Readmission events will be adjudi cated by a Clinical Event Comm ittee 
consisting of 2-[ADDRESS_116141] with patients enrolled in 
the study. 
 
KDIGO AKI Definition1:  
 AKI is defined by [CONTACT_39780] f ollowing 3 criteria:  
R O P A - D O P  S t u d y _  N A _ 0 0 0 8 3 6 2 9 ,  8 / 8 / 1 3  
 
 
1 4  
 1 .  I n c r e a s e  i n  s e r um  c r e a t i n i n e  b y  ≥ 0 . 3  m g / d l  ( ≥  2 6 . 5  μm o l / l )  w i t h i n  4 8  
h o u r s ;  O R   
2 .  I n c r e a s e  i n  s e r um  c r e a t i n i n e  t o  ≥ 1 . 5  t im e s  b a s e l i n e ,  w h i c h  i s  k n o w n  o r  
p r e s um e d  t o  h a v e  o c c u r r e d  w i t h i n  p r i o r  7  d a y s ;  O R   
3 .  U r i n e  v o l um e  < 0 . 5  m l / k g / h  f o r  6  h o u r s   
S t a g e s  o f  A K I  a s  d e f i n e d  b y  K D I G O  C r i t e r i a  a r e  a s  f o l l o w s :   
≥ ≥
≥
≥ ≥≥
≥
 
 
 
a .  S t a t i s t i c a l  p l a n  i n c l u d i n g  s am p l e  s i z e  j u s t i f i c a t i o n  a n d  i n t e r i m  d a t a  a n a l y s i s .  
 
1 .  O v e r v i e w :  
a .  T h i s  i s  a  f a c t o r i a l  d e s i g n  s t u d y  e v a l u a t i n g  t w o  s im u l t a n e o u s  u n r e l a t e d  
i n t e r v e n t i o n s .   S am p l e  s i z e  j u s t i f i c a t i o n  a n d  p r im a r y  e n d p o i n t  a n a l y s i s  
i s  d e s c r i b e d  b e l o w .    
 
2 .  A n a l y s i s  o f  P r im a r y  E n d p o i n t s :   
 
a .  T h e  p r im a r y  a n a l y s i s  w i l l  b e  c o n d u c t e d  o n  a n  i n t e n t i o n - t o - t r e a t  b a s i s .   
N o n - p a r am e t r i c  t e s t i n g  f o r  t h e  c o n t i n u o u s  p r im a r y  e n d p o i n t  
( c r e a t i n i n e )  w i l l  b e  p e r f o rm e d  u s i n g  t h e  W i l c o x o n -M a n n -W h i t n e y  U  
t e s t .   C o n f i rm a t o r y  t e s t  f o r  i n t e r a c t i o n  b e t w e e n  d o p am i n e  a n d  d i u r e t i c  
s t r a t e g y  w i l l  b e  p e r f o rm e d  w i t h  l i n e a r  r e g r e s s i o n  a n a l y s i s  w i t h  
d o p am i n e * d i u r e t i c  t e rm ,  p = 0 . 1 0  f o r  s i g n i f i c a n c e .  
 
3 .  S am p l e  S i z e  J u s t i f i c a t i o n :   
 
a .  A  d i f f e r e n c e  o f  3 0%  i n  c r e a t i n i n e  p r e  a n d  p o s t -  t r e a tm e n t  i s  c o n s i d e r e d  
t o  b e  c l i n i c a l l y  m e a n i n g f u l .  S e t t i n g  p a r am e t e r s  a s  f o l l o w s :  t w o - s i d e d ,  
a l p h a  ( T y p e  I  e r r o r  r a t e )  o f  0 . 0 5 ,  p o w e r  o f  0 . 8 0 ,  a n d  u s i n g  m e a n  
c r e a t i n i n e  c a l c u l a t i o n s  b a s e d  o n  o u r  o w n  r e t r o s p e c t i v e  e x p e r i e n c e  a t  
ROPA-DOP Study_ NA_00083629, 8/8/13 
 
 
15 
 Johns Hopkins as well as data from prior studies in patients ad mitted 
with ADHF, we estimate a sample size of approximately 63 patien ts 
per treatment arm.  This transl ates to 63 patients assigned to the 
diuretic-only treatment arm (intermittent bolus and continuous)  and 63 
patients assigned to the low-dose dopamine arm (in addition 
intermittent bolus diuretic and continuous diuretic treatment).   Taking 
into account drop-out rate, we plan to enroll 140 patients (70 per 
treatment arm; 34 per specific treatment strategy).   
4. Randomization:  
a. Patients will be randomized i n a blinded fashion to one of four 
treatment arms upon enrollment.  We plan to perform block randomization into the treatment  arms and plan to stratify pati ents by 
[CONTACT_545], CKD status, and receipt of  IV contrast dye (during the sa me 
admission), as these factors are felt to be significantly assoc iated with 
the development of AKI.    
5. Analysis of Secondary Endpoints:  
a. Summaries of continuous variables will be displayed using the mean, standard deviation, and median. For nominal variables, the number and frequency of subjects in each cat egory will be presented. Stati stical 
tests with p-values < 0.[ADDRESS_116142] will be removed fr om the trial if the above men tioned scenarios 
from Section 5 were to occur:   
i. The development of hemodynamic instability including hypotensio n (SBP 
< 90), hypertensive emergency, or unstable arrhythmias (SVT or VT)  
ii. The development of pulmonary ede ma requiring inotropes or vasop ressor 
or more than 50% inspi[INVESTIGATOR_1401]. 
iii. The development of acute coronary syndrome. 
iv. The development of acute kidney injury as follows:  
a. If the patient develops Sta ge II AKI (by [CONTACT_104746])
1, the 
study treatment will be held and a clinical decision will be ma de 
whether to resume or discontinue treatment drug 
b. If the patient develops Stage III AKI (by [CONTACT_104746])1, the 
study treatment will be discont inued and the patient will be 
classified as treatment failu re and followed only for outcome 
recording.  
i. The need for renal replacement therapy 
ii. New atrial fibrillation or  other supraventricular 
tachyarrhythmia 
iii. Sustained ventricular arrhythmias 
ROPA-DOP Study_ NA_00083629, 8/8/13 
 
 
16 
 v. Requirement of furosemide dose increase beyond the study maximu m of 
200 IV twice daily (or 400 IV ove r 24 hrs), or the need for add ition of 
thiazide diuretic. 
 
The investigators will report all adverse events to the IRB and will follow these patients throughout the duration of the study.  
 
8. Risks 
a. Medical risks, listing all proce dures, their major and minor ri sks and expected 
frequency. 
Furosemide is considered a standa rd of care diuretic for the tr eatment of acute heart 
failure. While it is a commonly used medication, the risks commonly associated with 
furosemide include (but are not  limited to) acute kidney injury  (pre-renal azotemia, acute 
interstitial nephri tis), and electrolyte disturbances (hypokale mia, hypomagenesemia). 
Severe but uncommon risks of fur osemide include orthostatic hyp otension, drug 
hypersensitivity syndrome, erythema multiforme, erythroderma, S tevens-Johnson 
syndrome, toxic epi[INVESTIGATOR_194], pancreatitis, aranulocyto sis, aplastic anemia, 
thrombocytopenia, anaphylact oid reaction, and anaphylaxis. 
 
Diminished hearing or deafness, r eversible and i rreversible, has been reported with the 
use of furosemide. Usually, t he effects on hearing are associat ed with fast injections, 
severe renal impairment (lo ss of kidney function), hypoproteine mia (low protein in the 
blood), use of higher than recomm ended doses or in combination with other ototoxic 
agents.  The effects on hearing are rare and would more likely occur from intermittent 
doses, than continuous infusions. 
 
 
 Dopamine is often used in the tre atment of acute heart failure  exacerbation to assist 
with diuresis, particularly when t here is a risk of development  of acute kidney injury. The 
common side effects and risks associated with low-dose dopamine include chest pain, 
increase in blood pressure, fast or irregular heart rates, injection site reaction, and hair follicles may stand erected.  Serious but uncommon risks includ e ectopic beats, 
ventricular arrhythmia, wide QRS complex, and gangrenous disord er. 
 
 
b. Steps taken to minimize the risks.  
All patients will be admitted to telemetry floor beds for close  monitoring of 
hemodynamic state.  All patient s will undergo vital sign checks  every 4-[ADDRESS_116143] of care for inpatient acute he art failure management 
includes twice daily basic metabo lic profile check to assess re nal function and 
electrolytes.  A standardized electrolyte replacement protocol will be enforced for all 
patients to minimize the risk of cardiac arrhythmias in the set ting of diuresis. In patients 
whose GFR is below and/or creat inine is above the cutoff for th e standard electrolyte 
repletion protocol, this will be managed by [CONTACT_104753]. In addition, the 
ROPA-DOP Study_ NA_00083629, 8/8/[ADDRESS_116144] an y signs of 
hemodynamic instability  (please refer to Exc lusion criteria). This includes hypotension 
for any reason (SBP < 90), hypertensive emergency (SBP >200 or signs of end-organ damage), supraventricular tachycardias (atrial fibrillation, at rial flutter) that are not 
responsive to rate control therap ies, or ventricular arrhythmia s beyond occasional PVCs 
or NSVT.  
In the dopamine strategy group, if the subject develops tachyca rdia as defined by 
[CONTACT_104754] >120 beats per min the infusion will be stopped. After 3 hours, if heart rate is 
< 120 beats per min, the IV infusion will be restarted at 1 μg/kg/min (<50% of the previous dose). If the heart rate  is >120 beats per min after 3  hours or if tachycardia 
recurs, then the infusion will be terminated and this will be c aptured as “treatment 
failure.”   
 
c. Plan for reporting unanticipated  problems or study deviations. 
 
 All unanticipated problems such a s transfers to the CCU, atrial  or ventricular 
arrhythmias, acute coronary syndrome, or acute renal failure re quiring renal replacement 
therapy will be re ported within [ADDRESS_116145] in their heart failure management.  In 
addition, all patients will receiv e heart failure teaching from  the HF nursing staff and 
follow up appointments in the Hear t Failure Bridge Clinic will be made for these patients.  
  
10. Payment and Remuneration 
ROPA-DOP Study_ NA_00083629, 8/8/13 
 
 
18 
 a. Detail compensation for particip ants including possible total c ompensation, 
proposed bonus, and any proposed re ductions or penalties for not completing the 
protocol. 
 
There is no compensation to the pa tients enrolled in this study . 
 
11. Costs 
a. Detail costs of study procedure(s)  or drug (s) or substance(s) to participants and 
identify who will pay for them. 
 
    
The cost of dopamine for this tr ial and non-standard laboratory  tests (cysta tin-C, pro-BNP 
following admission value) will be  compensated for through research funds of the PI [INVESTIGATOR_6254]-
Investigators.   
 
ROPA-DOP Study_ NA_00083629, 8/8/13 
 
 
19 
 References  
  
1. Khwaja A. KDIGO Clinical Prac tice Guidelines f or Acute Kidne y Injury. Nephron Clinical Practice 
2012;120:C179-C84. 
2. Roger VL, Go AS, Lloyd-Jones DM, et al. Heart disease and st roke statistics--2012 update: a report from 
the American Heart Association.  Circulation 2012;125:e2-e220. 
3. Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfiel d MM. Trends in prevalence and 
outcome of heart failure with pre served ejection fraction. N En gl J Med 2006;355:251-9. 
4. Lee DS, Gona P, Vasan RS, et a l. Relation of disease pathoge nesis and risk factors to heart failure with 
preserved or reduced ejection fraction: insights from the framingham heart study of the national heart, lung, and 
blood institute. Circulation 2009;119:3070-7. 5. Bhatia RS, Tu JV, Lee DS, et a l. Outcome of heart failure wi th preserved ejection fraction in a population-
based study. N Engl J Med 2006;355:260-9. 6. Felker GM, Lee KL, Bull DA, et al. Diuretic strategies in pa tients with acute decompensated heart failure. 
N Engl J Med 2011;364:797-805. 
7. Giamouzis G, Butler J, Starling RC, et al. Impact of dopamin e infusion on renal function in hospi[INVESTIGATOR_104741]: results o f the Dopamine in Acute Decomp ensated Heart Failure (DA D-HF) Trial. J Card Fail 
2010;16:922-30. 8. Waikar SS, Liu KD, Chertow GM. Diagnosis, epi[INVESTIGATOR_58109] o utcomes of acute kidney injury. Clin J 
Am Soc Nephrol 2008;3:844-61. 
9. Dries DL, Exner DV, Domanski MJ, Greenberg B, Stevenson LW. The prognostic implications of renal 
insufficiency in asymptomatic and symptomatic patients with lef t ventricular systolic dysfunction. J Am Coll 
Cardiol 2000;35:681-9. 10. Gottlieb SS, Abraham W, Butler J, et al. The prognostic imp ortance of different d efinitions of worsening 
renal function in congestive h eart failure. J Card Fail 2002;8: 136-41. 
11. Wang DJ, Dowling TC, Meadows D, et al. Nesiritide does not improve renal function in patients with 
chronic heart failure and worseni ng serum creatinine. Circulati on 2004;110:1620-5. 
12. Leier CV, Bambach D, Thompso n MJ, Cattaneo SM, Goldberg RJ, Unverferth DV. Central and regional 
hemodynamic effects of intravenous isosorbide dinitrate, nitrog lycerin and nitroprusside in patients with congestive 
heart failure. Am J Cardiol 1981;48:1115-23. 13. Elkayam U, Bitar F, Akhter MW , Khan S, Patrus S, Derakhshan i M. Intravenous nitroglycerin in the 
treatment of decompensated heart failure: potential benefits an d limitations. J Cardiovasc Pharmacol Ther 
2004;9:227-41. 14. Bayram M, De Luca L, Massie MB, Gheorghiade M. Reassessment  of dobutamine, dopamine, and 
milrinone in the management of acute heart failure syndromes. A m J Cardiol 2005;96:47G-58G. 
15. Friedrich JO, Adhikari N, He rridge MS, Beyene J. Meta-analy sis: low-dose dopamin e increases urine 
output but does not prevent renal dysfunction or death. Ann Intern Med 2005;142:510-24. 16. Ungar A, Fumagalli S, Marini M, et al. Renal, but not syste mic, hemodynamic eff ects of dopamine are 
influenced by [CONTACT_104755]. Crit Ca re Med 2004;32:1125-9. 
17. Elkayam U, Ng TM, Hatamizadeh P, Janmohamed M, Mehra A. Ren al Vasodilatory Act ion of Dopamine 
in Patients With Heart Failure: Magnitude of Effect and Site of  Action. Circulation 2008;117:200-5. 
  